• Molecular NameOxamniquine
  • SynonymNA
  • Weight279.34
  • Drugbank_IDDB01096
  • ACS_NO21738-42-1
  • Show 3D model
  • LogP (experiment)2.24
  • LogP (predicted, AB/LogP v2.0)2.15
  • pkaN/A
  • LogD (pH=7, predicted)0.39
  • Solubility (experiment)0.82 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.55
  • LogSw (predicted, AB/LogsW2.0)2.0
  • Sw (mg/ml) (predicted, ACD/Labs)4.64
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA93.12
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anthelmintic with schistosomicidal activity against Schistosoma mansoni,
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is extensively metabolised to inactive metabolites, principally the 6-carboxy derivative, which are excreted in the urine.
  • Half life1~2.5 h
  • ExcretionAbout 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A